All Legal & Compliance articles
-
ArticleNavigating IND delays: strategic options for early-phase biotech development
As IND timelines lengthen, early-stage biotechs face growing uncertainty in early clinical planning. This article explores how sponsors are increasingly diversifying their development strategies and why New Zealand represents an attractive option.
-
ArticleWhy most labs are not ready for AI: Cenevo shares what must change
Most labs want to use AI, but few have the digital foundations to support it. Cenevo’s leaders explain why progress is slow and what laboratories must fix before AI can deliver real value.
-
NewsELRIG appoints Dr Kelly Gray and Dr Elaine Duncan to board
ELRIG has appointed Dr Kelly Gray and Dr Elaine Duncan to its board, bringing extensive expertise to lead scientific programmes and early career initiatives.
-
ArticleDrug discovery integration takes centre stage at SLAS Boston 2026
Drug discovery has no shortage of powerful technologies, but the challenge now is making them work together. At SLAS Boston 2026, researchers and technology developers revealed how laboratories are connecting the entire experimental pipeline.
-
ArticleThe map and compass: integrating BD&L early to de-risk drug discovery
In drug discovery, great science alone is not enough because commercial viability ultimately decides which programmes survive and attract partners. This Q&A explores how integrating Business Development and Licensing (BD&L) from the earliest stages can guide R&D strategy, sharpen decisions and de-risk the path to market.
-
ArticleReplacing animals in science: what the UK’s new strategy means
The UK has set out a strategy to replace animal testing, but delivering change will depend as much on regulation as on technology. Dr Emma Grange, Director of Science and Regulatory Affairs at Cruelty Free International, examines what the policy signals for research, drug discovery and safety assessment.
-
OpinionAI in drug discovery: predictions for 2026
As AI drug discovery enters 2026, the industry faces a pivotal year of clinical tests, regulatory clarity, and market consolidation. Here, Dr Raminderpal Singh examines where AI is delivering measurable gains in early discovery, where hype outpaces reality and why Phase III results will determine whether the technology can truly ...
-
NewsDrug Target Review’s women in STEM
For International Day of Women and Girls in Science, Drug Target Review highlights articles published over the past year that were authored by women, celebrating their contributions to research.
-
NewsNew paper warns against phasing out animal testing too quickly
A push by the US Food and Drug Administration to phase out animal testing in drug development could improve efficiency and reduce animal suffering, but experts warn that moving too quickly may pose risks to patient safety.
-
ArticleDrug development in 2026: NAMs, safety and regulatory changes
2026 is set to be a pivotal year for drug discovery, with advances in NAMs and evolving regulatory approaches promising faster, safer early drug development and accelerated delivery of therapies for patients with rare or unmet medical needs.
-
ArticlePeptides in practice: what it takes to advance these therapies to clinic
Peptide therapeutics are emerging as a powerful class of medicines capable of targeting diseases that challenge traditional modalities. This article reveals their rising clinical impact and the key development, safety and translational challenges that must be addressed to bring them successfully to patients.
-
NewsLife sciences face ‘scientific content crisis’ in AI adoption
A new survey by the Pistoia Alliance reveals a growing ‘scientific content crisis’ in life sciences, showing that incomplete data and weak governance are limiting the accuracy and adoption of AI in research and development.
-
ArticleThe mother of invention: from steam engines to AI-designed drugs
Every great leap in history started with a single, urgent need. Now AI is emerging as the next great engine of invention, transforming the future of medicine faster than ever imagined.
-
ArticleAI and policy reform set to reshape UK drug development
BCG’s Chris Meier outlines how advances in AI and new UK policies could accelerate drug development, streamline clinical trials and strengthen the country’s life sciences sector.
-
ArticleTransforming central labs with automation and AI: setting new standards for modern trials
Demands on central laboratories are consistently increasing, heightening the challenge to deliver operational excellence and the highest standard of scientific integrity with both speed and agility. ICON Laboratories is transforming the way we leverage data and intelligent operational models to meet evolving trial needs.
-
ArticleResetting retinal networks with a gene-agnostic approach
What if treating blindness did not mean fixing a single faulty gene? Find out how modifier gene therapy is designed to protect vision by targeting broader retinal pathways.
-
NewsUK Government announce plans to phase out animal testing for drugs
The UK government have announced a new strategy to phase out animal testing in scientific research, aiming to replace traditional experiments with innovative human-relevant methods such as organ-on-a-chip systems and AI analysis.
-
ArticleBeyond weight loss: the gap in current drug development for obesity
Current obesity drug development remains overly focused on short-term weight reduction, despite obesity being a chronic, multifactorial disease. Broader, mechanism-driven approaches are needed to ensure durable efficacy, safety and accessibility.
-
ArticleAn ethical shift in NHP research: iPSC-derived cardiomyocytes for safer pharmacology
As regulators move to phase out primate testing, NHP-derived iPSC cardiomyocytes are emerging as a scalable, ethical and scientifically robust alternative - offering drug developers a clear path to faster, more predictive, and more responsible innovation.
-
ArticleFast-tracking advanced therapies without compromising regulatory success
Early planning for potency CQAs, comparability and evolving global regulations can set advanced therapies on the fastest path to approval. Dr Christian Schneider shares how to prepare from the start to accelerate development without compromising the evidence regulators expect.